RKLB Rocket Lab Corp Insider Trading

CEO Peter Beck sold 3,275,779 shares for $286,410,195.56 across three days (2026-07-06 to 2026-07-08) under a 10b5-1 plan.

Peter Beck executed 24 separate sales totaling 3,275,779 shares for $286,410,195.56 on a scheduled 10b5-1 trading plan adopted on 2026-03-27, reducing his RKLB holdings by -65.5% from 5,000,000 shares to 1,724,221 shares. The multi-day sale was conducted at a blended average price of $87.43, while the stock currently trades at $83.35 (down -44.8% from its 52-week high of $151.00 and down -26.7% over the prior 30 days). Beck's prior five sales at RKLB all occurred on 2026-03-02 and showed 90-day returns ranging from +103.2% to +114.7%, while his cross-ticker track record of 20 prior sells averaged 90-day returns of +44.1%. Because this transaction is pre-scheduled under a 10b5-1 plan rather than discretionary, the sale reflects a contractual commitment executed at market prices rather than a signal of recent conviction or market timing. The scale of the divestiture and the company's unprofitable status (full-year net income negative, latest quarter net income $-45.0M) against $200,348,000 in quarterly revenue merit scrutiny of whether prior transaction planning reflected different market conditions.

SVP & General Counsel Arjun Kampani sells 88,000 shares of RKLB at $107.98; stock down 15.8% in 30 days and 29.0% from 52-week high

Arjun Kampani, SVP & General Counsel of Rocket Lab, sold 88.0K shares at $107.98 for $9,502,240.00 on 2026-06-18, reducing his holdings by 25.0% from 352.7K to 264.7K shares. The sale occurs as RKLB stock has declined 15.8% over the prior 30 days and sits 29.0% below its 52-week high of $151.00. Across his cross-ticker open-market history, Kampani's prior 20 sells averaged -5.8% return in 30 days and +71.4% in 90 days, with a well-timed sell rate of 0.00% — indicating his past sales have consistently been followed by stock appreciation rather than declines. At RKLB specifically, all 5 of his prior trades (conducted on 2026-05-28) remain outcomes-unmeasurable. The company is unprofitable (full-year net income was negative) despite strong revenue growth of +38.0% annually and $200.3M in latest quarterly revenue. The transaction is sized materially but falls within the expected variance of a large shareholder's periodic portfolio activity.

Director Alexander R Slusky sold 40,000 shares of RKLB at $123.60 on 2026-06-02, retaining 334,675 shares; stock now at $110.08, -27.1% from 52-week high.

Director Alexander R Slusky sold 40,000 shares (10.7% of pre-transaction holdings) at $123.60, reducing his stake from 374,675 to 334,675 shares. The sale occurred when RKLB was trading near its 52-week highs and has since declined 27.1% to the current price of $110.08. Examining his execution history at this ticker: Slusky completed four sales on 2026-05-12 that were all well-timed, with 30-day and 90-day returns ranging from +19.6% to +24.7%—meaning the stock fell after those sales, validating the exit timing. This current sale on 2026-06-02 follows immediately after that streak, occurring when the stock was elevated; the subsequent 27.1% decline suggests similar positioning ahead of near-term weakness. Investors should note that RKLB remains unprofitable (net income $-45.0M on quarterly revenue of $200.3M) while trading at a $63.7B market cap, even as annual revenue grew 38.0%.

Director Alexander Slusky sold 60,000 RKLB shares ($8,964,092.00) at $149.10–$150.00; stock now at $122.39 (-19.0% from 52-wk high).

Alexander R Slusky, a Director at Rocket Lab, executed 2 separate sales totaling 60,000 shares for $8,964,092.00 at prices of $149.10 and $150.00 on 2026-05-28, reducing his holdings by 13.8% to 374,675 shares. The sales occurred near the 52-week high of $151.00; the current price of $122.39 is now 19.0% below that peak, and the stock has gained 55.3% over the 30 days since the transaction but fallen from the transaction prices. Slusky's prior trades at this ticker show poor 90-day timing (1 of 5 prior sells were well-timed), and his cross-ticker track record shows average 90-day returns of +8.5% following his sells, indicating he has historically sold before rallies rather than before declines. The company's fundamentals remain under pressure: it reported negative net income of $-45,022,000.00 on quarterly revenue of $200,348,000.00 despite 38.0% annual revenue growth, and remains unprofitable on a full-year basis. The timing and size of this director sale warrant attention given the proximity to the 52-week high and the company's ongoing unprofitability.

COO Frank Klein sells 36,860 shares at blended avg $147.42 under pre-arranged 10b5-1 plan; stock now $122.39.

Frank Klein, COO of Rocket Lab, executed 8 separate sales totaling 36,860 shares for $5,433,997.64 on 2026-05-28 under a 10b5-1 trading plan adopted 2025-09-19, reducing his holdings by 3.5% to 1,006,987 shares. The transactions were spread across prices from $143.05 to $149.99, with a blended average of $147.42. The current stock price of $122.39 represents a 19.0% decline from the 52-week high of $151.00, placing the sale prices near the recent peak of the stock's range. As a scheduled transaction under a pre-arranged plan, this sale carries no timing implication; however, the fact that prior sales by this insider at RKLB on 2026-03-04 showed negative 30-day returns (-3.6% to -8.2%) while producing strong 90-day gains (+103.5% to +113.8%) suggests a historical pattern where this ticker has recovered significantly after near-term declines. The company remains unprofitable on a full-year basis with net income of $-45,022,000.00, though quarterly revenue reached $200,348,000.00 with annual growth of +38.0%.

Rocket Lab President Marvin Clevenger sold 3,500 shares at $146.67 on 2026-05-28 (total: $513,355.85), reducing stake to 474.0K shares.

Marvin Bradford Clevenger, President of Rocket Lab USA, Inc, executed a modest sale of 3,500 shares (3.5K shares) representing -0.7% of his pre-transaction holdings, at a price of $146.67 per share. The sale occurred when the stock stood 19.0% below its 52-week high of $151.00, despite strong recent momentum (30-day change: +55.3%, 90-day change: +74.5%). While the company remains unprofitable with a full-year net income of $-45.0M, it has achieved robust annual revenue growth of +38.0%, reaching $200.3M in the latest quarter. The magnitude and proportion of this sale are limited relative to Clevenger's remaining holdings of 473,975 shares (474.0K shares), and the absolute transaction size of $513,355.85 does not suggest a material shift in position.

SVP & General Counsel sold 23,804 shares at blended avg $147.43 on 2026-05-28 (scheduled 10b5-1 plan), stock now -19.0% from 52-week high

Arjun Kampani executed 8 separate sales totaling 23,804 shares for $3,509,510.74 on 2026-05-28 at prices ranging from $143.15 to $150.26, reducing his holdings by 6.3%. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-19, meaning the sales were scheduled rather than discretionary timing decisions. The stock has since declined to $122.39, trading 19.0% below its 52-week high of $151.00. Notably, his prior trades at RKLB (5 sales in March 2026) showed negative 30-day returns (ranging from -4.0% to -8.6%) followed by substantial 90-day gains (102.8% to 113.0%), a pattern that does not appear in his cross-ticker track record where the average 90-day return after 20 prior sells was +72.2%. The company is currently unprofitable with net income of $-45,022,000.00 against revenue of $200,348,000.00, though it achieved annual revenue growth of +38.0%.

SVP & General Counsel Arjun Kampani sold 70,000 RKLB shares for $10.2M via 10b5-1 plan on 2026-05-27

Arjun Kampani executed 2 separate sales totaling 70,000 shares for $10,158,783.39 as part of a pre-arranged 10b5-1 trading plan, reducing his holdings by -15.7% to 376,509 shares. The transaction was scheduled, not discretionary. His prior 5 sales at RKLB showed mixed near-term outcomes (30-day returns ranged from -8.6% to -4.0%), though longer-term results were consistently positive (90-day returns ranged from +102.8% to +113.0%), but these historical patterns do not apply to judging this particular scheduled sale. The company generated $200.3M in quarterly revenue with an annual growth rate of +38.0% but reported a net loss of $-45.0M, indicating ongoing profitability challenges despite strong top-line growth.

RKLB Director Slusky sells 100.0K shares for $11.8M near 52-week high; stock up +83.5% in 30 days

Director Slusky Alexander R sold 100,000 shares of Rocket Lab Corp (RKLB) for $11.8M across multiple transactions on 2026-05-12, with sale prices ranging from $115.05 to $120.01, while the current price sits at $132.55 — +4.2% above the 52-week high of $127.24 following a +83.5% surge in the past 30 days. This sale represents a meaningful reduction from a still-substantial post-transaction holding of 434.7K shares. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 2 prior sells, and his 2 prior trades specifically at RKLB — both sells in December 2024 — showed subsequent 90-day declines of -18.9% and -15.6%, reinforcing a pattern of well-timed exits at this ticker. Rocket Lab remains unprofitable with net income of $-45,022,000.00 on latest-quarter revenue of $200.3M, meaning the stock's $76.7B market cap rests heavily on growth expectations, making this large insider sale during an extended momentum run a signal worth monitoring.

Director Saintil Merline sells 18,126 shares of RKLB at $75.04; stock down -25.8% from 52-week high, insider's recent RKLB sells preceded sharp declines.

Saintil Merline sold 18,126 shares at $75.04, reducing holdings by 6.5% to 261,903 shares. The timing pattern is noteworthy: his prior two RKLB sales (2026-01-14 and 2026-01-13) both preceded sharp 30-day declines of -25.1% and -23.8% respectively, and his cross-ticker sell history shows a 100.00% well-timed rate with an average 90-day return of -12.0%. The current price of $71.48 sits -25.8% from the 52-week high of $96.30, consistent with the pattern of declines following his prior recent transactions at this ticker. RKLB remains unprofitable with net income of $-18,257,000.00 against revenue of $155,080,000.00, though annual revenue growth stands at 38.0%. The sequence of insider sales immediately preceding multi-week selloffs warrants attention to whether subsequent market moves validate or contradict this pattern.